ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA panel snubs Johnson & Johnson’s rheumatoid arthritis drug sirukumab, citing worries about trial
August 07, 2017A panel of arthritis experts has overwhelmingly recommended against the approval of Johnson & Johnson's sirukumab. The panel voted 12 to 1 against approving the IL-6 monoclonal antibody for the treatment of rheumatoid arthritis after taking a dim view of
Pharma Sources Insight January 2025
